A5038532654- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Lymphoma Diagnosis and Treatment
- DNA Repair Mechanisms
- Chronic Myeloid Leukemia Treatments
- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- CRISPR and Genetic Engineering
- SARS-CoV-2 and COVID-19 Research
- Platelet Disorders and Treatments
- PARP inhibition in cancer therapy
- Acute Lymphoblastic Leukemia research
- Gastrointestinal Tumor Research and Treatment
- Blood disorders and treatments
- Diabetes Treatment and Management
- Neutropenia and Cancer Infections
- Renal Diseases and Glomerulopathies
- Advanced Breast Cancer Therapies
- Genomics and Chromatin Dynamics
- Blood groups and transfusion
- Carcinogens and Genotoxicity Assessment
- Methemoglobinemia and Tumor Lysis Syndrome
- Long-Term Effects of COVID-19
- Hemophilia Treatment and Research
- CAR-T cell therapy research
Istituto Superiore di Sanità
2023-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2020-2023
National Institute on Aging
2023
Istituto Nazionale Biostrutture e Biosistemi
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Ospedale Maggiore
2021
University of Milan
2020
Ibrutinib represents extraordinary progress in the treatment of chronic lymphocytic leukemia (CLL). However, treatment-related adverse events limit benefit this agent. This observational, multicenter study focused on incidence, risk factors, and prognostic impact infections 494 patients with CLL treated an ibrutinib-based treatment. was given to 89 (18%) previously untreated (combined rituximab, 24) 405 (82%) relapsed/refractory patients. Pneumonia (PN), grade ≥3 non-opportunistic (NOI),...
Ibrutinib-associated atrial fibrillation (IRAF) emerged among the adverse events of major interests in ibrutinib-treated patients as real-world studies showed a higher incidence compared to clinical trials. We prospectively analyzed predictors IRAF 43 single-center consecutive affected by chronic lymphocytic leukemia that started therapy with ibrutinib between 2015 and 2017. Key secondary endpoints were describe management survival outcomes. During median follow-up period 52 months, we...
Hematologic patients show lower responses to SARS-CoV-2 vaccines, but predictors of seroconversion are lacking. In this prospective cohort study, hematologic undergoing mRNA vaccination at a single center in Milan, Italy, were sampled for anti-Spike and anti-Nucleocapsid IgG titer 5 ± 1 weeks 3 months from the second vaccine dose. Patients (N = 393) received either BNT162b2 (Pfizer-BioNTech, 48%) or MRNA-1273 (Moderna, 52%), 284 (72%) seroconverted 100% persisted months. Non-response was...
Abstract The MUS81 complex is crucial for preserving genome stability through resolution of branched DNA intermediates in mitosis and also the processing deprotected replication forks BRCA2-deficient cells. Because existence two different complexes mammalian cells that act M- or S-phase, whether how PARPi sensitivity affected by loss function unclear. Here, using a mutant impairs its M-phase, we show viability but not their requires fully-functional mitosis. In contrast, expression...
Background: The efficacy and tolerability of venetoclax (VEN) retreatment in patients (pts) with chronic lymphocytic leukemia (CLL) relapsing after VEN-based fixed-duration regimens still remains to be clarified. Data collected small cohorts suggest that VEN can effective well tolerated, thus it is worth exploiting larger well-characterized pts CLL. Aims: We analyzed the safety relapsed/refractory CLL enrolled our clinical trial IMPROVE (NCT04754035). Methods: Pts into study were treated...
ABSTRACT The WRN protein mutated in the hereditary premature aging disorder Werner syndrome plays a vital role handling, processing, and restoring perturbed replication forks. One of its most abundant partners, Replication Protein A (RPA), has been shown to robustly enhance helicase activity specific cases when tested vitro . However, significance RPA-binding at forks vivo remained largely unexplored. In this study, we have identified several conserved phosphorylation sites acidic domain...
ABSTRACT The MUS81 complex is crucial for preserving genome stability through resolution of branched DNA intermediates in mitosis and also the processing deprotected replication forks BRCA2-deficient cells. Because existence two different complexes mammalian cells that act M or S-phase, whether how PARPi sensitivity affected by loss function unclear. Here, using a mutant impairs its M-phase, we show viability but not their requires fully-functional mitosis. In contrast, expression...
B-cell lymphoproliferative diseases may be associated with acquired hemostasis disorders, such as hemophilia A (AHA) caused by autoantibodies that neutralize factor VIII activity, and δ-storage pool deficiency, an abnormality of platelet function due to defective dense granules impaired secretion. We describe the case a 67-year-old man in whom these two bleeding disorders were concomitantly present first clinical manifestation indolent non-Hodgkin lymphoma. Immunosuppressive therapy...